Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Cancer Immunol Immunother. 2020 Feb 8;69(5):731–744. doi: 10.1007/s00262-020-02504-z

Fig 4.

Fig 4

Simulated progression over 36h (a through d) of a representative tumor lesion after exposure to a medium strength (λeffectN = 280) of a hypothetical “agent affecting macrophage polarization” (AAMP), simulating an immune therapeutic (as a fraction of the maximum in the vasculature) shifting the M1:M2 ratio to 3.0:1, in conjunction with a bolus injection of MSV-nab-PTX drug-loaded nanoparticles. Colors as in Fig 3. Bar= 200 μm.